{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:44:13Z","timestamp":1790419453202,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00198-025-07687-8","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T22:25:51Z","timestamp":1756938351000},"page":"2207-2219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of treatment initiation for secondary fracture prevention in the older population: Japanese Bone-fracture Osteoporosis in Late-stage population Database study (J-BOLD) \u2013 emulation of a randomized target trial"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-5072","authenticated-orcid":false,"given":"Manabu","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"7687_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"key":"7687_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-014-0182-3","volume":"9","author":"SW Wade","year":"2014","unstructured":"Wade SW, Strader C, Fitzpatrick LA et al (2014) Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos 9:182. https:\/\/doi.org\/10.1007\/s11657-014-0182-3","journal-title":"Arch Osteoporos"},{"key":"7687_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldaa005","volume":"133","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM et al (2020) The epidemiology of osteoporosis. Br Med Bull 133:105\u2013117. https:\/\/doi.org\/10.1093\/bmb\/ldaa005","journal-title":"Br Med Bull"},{"key":"7687_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00774-018-0916-1","volume":"37","author":"S Fujiwara","year":"2019","unstructured":"Fujiwara S, Zhao X, Teoh C et al (2019) Disease burden of fractures among patients with osteoporosis in Japan: health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and economic costs. J Bone Miner Metab 37:307\u2013318. https:\/\/doi.org\/10.1007\/s00774-018-0916-1","journal-title":"J Bone Miner Metab"},{"key":"7687_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"7687_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2014.125","volume":"10","author":"SE Sattui","year":"2014","unstructured":"Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592\u2013602. https:\/\/doi.org\/10.1038\/nrendo.2014.125","journal-title":"Nat Rev Endocrinol"},{"key":"7687_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1060028020970518","volume":"55","author":"SA Williams","year":"2021","unstructured":"Williams SA, Daigle SG, Weiss R et al (2021) Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother 55:821\u2013829. https:\/\/doi.org\/10.1177\/1060028020970518","journal-title":"Ann Pharmacother"},{"key":"7687_CR8","unstructured":"Statistics Bureau, Ministry of Internal Affairs and Communications, Japan (2024) Statistical Handbook of Japan 2024. Statistics Bureau, MIC, Tokyo. https:\/\/www.stat.go.jp\/english\/data\/handbook\/index.html. Accessed 21 Feb 2025"},{"key":"7687_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/jbmr\/zjae040","volume":"39","author":"M Schini","year":"2024","unstructured":"Schini M, Vilaca T, Vittinghoff E et al (2024) Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project. J Bone Miner Res 39:544\u2013550. https:\/\/doi.org\/10.1093\/jbmr\/zjae040","journal-title":"J Bone Miner Res"},{"key":"7687_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Beaudart C, Bruy\u00e8re O et al (2024) Evidence-based guideline for the management of osteoporosis in men. Nat Rev Rheumatol 20:241\u2013251. https:\/\/doi.org\/10.1038\/s41584-024-01094-9","journal-title":"Nat Rev Rheumatol"},{"key":"7687_CR11","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/jbmr\/zjae090","volume":"39","author":"TM Keaveny","year":"2024","unstructured":"Keaveny TM, Adams AL, Orwoll ES et al (2024) Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study. J Bone Miner Res 39:1424\u20131433. https:\/\/doi.org\/10.1093\/jbmr\/zjae090","journal-title":"J Bone Miner Res"},{"key":"7687_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-007-0544-4","volume":"19","author":"S Fujiwara","year":"2008","unstructured":"Fujiwara S, Nakamura T, Orimo H et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX\u2122). Osteoporos Int 19:429\u2013435. https:\/\/doi.org\/10.1007\/s00198-007-0544-4","journal-title":"Osteoporos Int"},{"key":"7687_CR13","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","volume":"29","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Od\u00e9n A et al (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747\u20131757. https:\/\/doi.org\/10.1007\/s00198-018-4502-0","journal-title":"Osteoporos Int"},{"key":"7687_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/jbmr.4806","volume":"38","author":"KF Axelsson","year":"2020","unstructured":"Axelsson KF, Litsne H, Lorentzon M (2020) The importance of recent prevalent fracture site for imminent risk of fracture \u2013 a retrospective, nationwide cohort study of older Swedish men and women. J Bone Miner Res 38:851\u2013859. https:\/\/doi.org\/10.1002\/jbmr.4806","journal-title":"J Bone Miner Res"},{"key":"7687_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","volume":"30","author":"A Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L et al (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30:79\u201392. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","journal-title":"Osteoporos Int"},{"key":"7687_CR16","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00198-022-06472-1","volume":"33","author":"S Fujiwara","year":"2022","unstructured":"Fujiwara S, Buchanan-Hughes A, Ng A et al (2022) Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision database. Osteoporos Int 33:2205\u20132216. https:\/\/doi.org\/10.1007\/s00198-022-06472-1","journal-title":"Osteoporos Int"},{"key":"7687_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00223-011-9545-6","volume":"90","author":"H Hagino","year":"2012","unstructured":"Hagino H, Sawaguchi T, Endo N et al (2012) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14\u201321. https:\/\/doi.org\/10.1007\/s00223-011-9545-6","journal-title":"Calcif Tissue Int"},{"key":"7687_CR18","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00198-024-07072-x","volume":"35","author":"M Lorentzon","year":"2024","unstructured":"Lorentzon M, Litsne H, Axelsson KF (2024) The significance of recent fracture location for imminent risk of hip and vertebral fractures\u2014a nationwide cohort study on older adults in Sweden. Osteoporos Int 35:1077\u20131087. https:\/\/doi.org\/10.1007\/s00198-024-07072-x","journal-title":"Osteoporos Int"},{"key":"7687_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract 26:1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"key":"7687_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.3877","volume":"35","author":"RB Conley","year":"2020","unstructured":"Conley RB, Adib G, Adler RA et al (2020) Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res 35:36\u201352. https:\/\/doi.org\/10.1002\/jbmr.3877","journal-title":"J Bone Miner Res"},{"key":"7687_CR21","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39:1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Miner Res"},{"key":"7687_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, Von B\u00fclow C et al (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 381:e068033. https:\/\/doi.org\/10.1136\/bmj-2021-068033","journal-title":"BMJ"},{"key":"7687_CR23","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC et al (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32:1951\u20131960. https:\/\/doi.org\/10.1007\/s00198-021-05942-2","journal-title":"Osteoporos Int"},{"key":"7687_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11914-011-0060-5","volume":"9","author":"WD Leslie","year":"2011","unstructured":"Leslie WD, Schousboe JT (2011) A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep 9:129\u2013140. https:\/\/doi.org\/10.1007\/s11914-011-0060-5","journal-title":"Curr Osteoporos Rep"},{"key":"7687_CR25","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-014-2755-9","volume":"25","author":"R Rizzoli","year":"2014","unstructured":"Rizzoli R, Branco J, Brandi M-L et al (2014) Management of osteoporosis of the oldest old. Osteoporos Int 25:2507\u20132529. https:\/\/doi.org\/10.1007\/s00198-014-2755-9","journal-title":"Osteoporos Int"},{"key":"7687_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 105:587\u2013594. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"7687_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10789","volume":"7","author":"P Bosco-L\u00e9vy","year":"2023","unstructured":"Bosco-L\u00e9vy P, Briot K, Mehsen-Cetre N et al (2023) Real-world effectiveness of osteoporosis medications in France: a nationwide cohort study. JBMR Plus 7:e10789. https:\/\/doi.org\/10.1002\/jbm4.10789","journal-title":"JBMR Plus"},{"key":"7687_CR28","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/jbmr.4693","volume":"37","author":"T Chattaris","year":"2020","unstructured":"Chattaris T, Oh G, Gouskova NA et al (2020) Osteoporosis medications prevent subsequent fracture in frail older adults. J Bone Miner Res 37:2103\u20132111. https:\/\/doi.org\/10.1002\/jbmr.4693","journal-title":"J Bone Miner Res"},{"key":"7687_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/jbmr.4498","volume":"37","author":"B Freyschuss","year":"2022","unstructured":"Freyschuss B, Svensson MK, Cars T et al (2022) Real-world effectiveness of anti-resorptive treatment in patients with incident fragility fractures\u2014the STORM cohort\u2014a Swedish retrospective observational study. J Bone Miner Res 37:649\u2013659. https:\/\/doi.org\/10.1002\/jbmr.4498","journal-title":"J Bone Miner Res"},{"key":"7687_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00198-007-0421-1","volume":"18","author":"S Morin","year":"2007","unstructured":"Morin S, Rahme E, Behlouli H et al (2007) Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int 18:1625\u20131632. https:\/\/doi.org\/10.1007\/s00198-007-0421-1","journal-title":"Osteoporos Int"},{"key":"7687_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00198-020-05380-6","volume":"31","author":"O Str\u00f6m","year":"2020","unstructured":"Str\u00f6m O, Lauppe R, Ljunggren \u00d6 et al (2020) Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporos Int 31:1525\u20131533. https:\/\/doi.org\/10.1007\/s00198-020-05380-6","journal-title":"Osteoporos Int"},{"key":"7687_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H (2022) Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J 5:190\u2013198. https:\/\/doi.org\/10.31662\/jmaj.2021-0189","journal-title":"JMA J"},{"key":"7687_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"7687_CR34","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1097\/MLR.0b013e3181484347","volume":"45","author":"V Sundararajan","year":"2007","unstructured":"Sundararajan V, Quan H, Halfon P et al (2007) Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care 45:1210\u20131215. https:\/\/doi.org\/10.1097\/MLR.0b013e3181484347","journal-title":"Med Care"},{"key":"7687_CR35","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"LM Hess","year":"2006","unstructured":"Hess LM, Raebel MA, Conner DA, Malone DC (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40:1280\u20131288. https:\/\/doi.org\/10.1345\/aph.1H018","journal-title":"Ann Pharmacother"},{"key":"7687_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ et al (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20:512\u2013522. https:\/\/doi.org\/10.1097\/EDE.0b013e3181a663cc","journal-title":"Epidemiology"},{"key":"7687_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S et al (2016) Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.04.014","journal-title":"J Clin Epidemiol"},{"key":"7687_CR38","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","volume":"49","author":"C Maringe","year":"2020","unstructured":"Maringe C, Benitez Majano S, Exarchakou A et al (2020) Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int J Epidemiol 49:1719\u20131729. https:\/\/doi.org\/10.1093\/ije\/dyaa057","journal-title":"Int J Epidemiol"},{"key":"7687_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40801-022-00343-1","volume":"10","author":"R Wakabayashi","year":"2023","unstructured":"Wakabayashi R, Hirano T, Laurent T et al (2023) Impact of \u201ctime zero\u201d of follow-up settings in a comparative effectiveness study using real-world data with a non-user comparator: comparison of six different settings. Drugs 10:107\u2013117. https:\/\/doi.org\/10.1007\/s40801-022-00343-1","journal-title":"Drugs"},{"key":"7687_CR40","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/jbmr\/zjae101","volume":"39","author":"W Fan","year":"2024","unstructured":"Fan W, Sun X, Leder BZ et al (2024) Zoledronic acid for hip fracture during initial hospitalization. J Bone Miner Res 39:1061\u20131070. https:\/\/doi.org\/10.1093\/jbmr\/zjae101","journal-title":"J Bone Miner Res"},{"key":"7687_CR41","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"key":"7687_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00198-011-1556-7","volume":"23","author":"M Osaki","year":"2012","unstructured":"Osaki M, Tatsuki K, Hashikawa T et al (2012) Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int 23:695\u2013703. https:\/\/doi.org\/10.1007\/s00198-011-1556-7","journal-title":"Osteoporos Int"},{"key":"7687_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101105","volume":"15","author":"I Laura","year":"2021","unstructured":"Laura I, Felicia B, Alexia C et al (2021) Which treatment to prevent an imminent fracture? Bone Rep 15:101105. https:\/\/doi.org\/10.1016\/j.bonr.2021.101105","journal-title":"Bone Rep"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07687-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:32:01Z","timestamp":1763382721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07687-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7687"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07687-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the principles of the Declaration of Helsinki and its amendments. Although informed consent was not obtained, the study used an anonymized dataset and was reviewed and approved by the Institutional Review Board of Asai Dermatology [approval number 2023022001]. The research plan was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry [UMIN000054784].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"MT has received payments for lectures, including speakers\u2019 bureau fees, from Asahi Kasei Pharma Corporation. MT has received consulting fees from Zimmer Biomet G.K.TH has received lecture fees from Asahi Kasei Pharma Corporation, Amgen K. K., Daiichi-Sankyo Healthcare\u00a0Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.NO received payments for lectures, including speakers\u2019 bureau fees, from Asahi Kasei Pharma Corporation, Amgen K. K., Daiichi-Sankyo Healthcare\u00a0Co., Ltd., and Teijin Pharma Ltd.YS is an employee of Datack Inc.SF has received lecture fees from Asahi Kasei Pharma Corporation, Teijin Parma LTD, UCB Japan\u00a0Co., Ltd., Amgen K.K. and GE Healthcare Japan,\u00a0and supervision fees from Medical Data Card, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}